News

Published on 24 Jan 2025 on Benzinga

Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock...

Article preview image

On Friday, Novo Nordisk A/S NVO released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration.

The trial investigated the safety, tolerability, pharmacokinetics, and proof-of-concept after once-weekly subcutaneous administrations of amycretin in 125 people with overweight or obesity.

Read the rest of the article
NYSE.NVO price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Are Weight-Loss Drugs Like Gym Memberships? The Answer Is Worth Billions

After analyzing data going back to 2016, one analyst thinks he has identified a seasonal pattern ...

The Wall Street Journal · via Yahoo Finance 29 Jan 2025
Is Novo Nordisk (NVO) the Best Stock to Buy and Hold for 2025?

We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are...

Insider Monkey · via Yahoo Finance 25 Jan 2025
Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock...

On Friday, Novo Nordisk A/S NVO released topline results from a phase 1b/2a trial with amycretin ...

Benzinga 24 Jan 2025
Why Novo Nordisk Stock Jumped a Lucky 7.7% Today

Friday morning. What Novo Nordisk announced Novo Nordisk describes its latest work as "a phase 1b...

Motley Fool · via Yahoo Finance 24 Jan 2025
Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock...

On Friday, Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with...

Benzinga · via AOL 24 Jan 2025
Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin

Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest...

Yahoo Finance · via AOL 24 Jan 2025
Ozempic maker’s stock surges. A trial of a new Novo Nordisk drug shows promise.

Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able t...

Market Watch 24 Jan 2025
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth...

Zacks · via Yahoo Finance 24 Jan 2025
Is Novo Nordisk (NVO) the Best Falling Stock to Invest in Right Now?

We recently published a list of 10 Best Falling Stocks to Invest in Right Now. In this article, w...

Insider Monkey · via Yahoo Finance 24 Jan 2025
Eli Lilly stock dips on Novo Nordisk's rival drug data By Investing.com

On Friday, Novo Nordisk released promising trial results for its obesity treatment, amycretin, wh...

Investing.com 24 Jan 2025

Copyright Statfolio @ 2025

Social Accounts